The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2023 Sep 27

PMID 37754502

Authors

Kazuyuki Numakura

Mizuki Kobayashi

Yumina Muto

Hiromi Sato

Yuya Sekine

Ryuta Sobu

Yu Aoyama

Yoshiko Takahashi

Syuhei Okada

Hajime Sasagawa

Shintaro Narita

Satoshi Kumagai

Yuki Wada

Naoko Mori

Tomonori Habuchi

Affiliations

Soon will be listed here.

Abstract

A recent approach to radiotherapy for prostate cancer is the administration of high doses of radiation to the prostate while minimizing the risk of side effects. Thus, image-guided radiotherapy utilizes advanced imaging techniques and is a feasible strategy for increasing the radiation dose. New radioactive particles are another approach to achieving high doses and safe procedures. Prostate brachytherapy is currently considered as a combination therapy. Spacers are useful to protect adjacent organs, specifically the rectum, from excessive radiation exposure.

Citing Articles

Multiple roles of circular RNAs in prostate cancer: from the biological basis to potential clinical applications.

Zheng X, Song L, Cao C, Sun S Eur J Med Res. 2025; 30(1):140.

PMID: 40016786 PMC: 11866600. DOI: 10.1186/s40001-025-02382-0.

The Role of Transurethral BPH Surgeries in Management of Urinary Symptoms in Prostate Cancer Patients, Narrative Review.

Elsaqa M, El Tayeb M Curr Urol Rep. 2024; 26(1):7.

PMID: 39352587 PMC: 11445351. DOI: 10.1007/s11934-024-01229-1.

[Contemporary treatment standards and trends of systemic therapy in metastatic hormone-sensitive prostate cancer-implementing study data in clinical practice].

Wenzel M, Banek S, Chun F, Mandel P Urologie. 2024; 63(12):1259-1265.

PMID: 39143396 PMC: 11618166. DOI: 10.1007/s00120-024-02410-7.

Risk factors for secondary bladder cancer following prostate cancer radiotherapy.

Jahreiss M, Heemsbergen W, Aben K, Incrocci L Transl Androl Urol. 2024; 13(7):1288-1296.

PMID: 39100827 PMC: 11291406. DOI: 10.21037/tau-23-667.

Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy.

Orlovskiy S, Gupta P, Roman J, Arias-Mendoza F, Nelson D, Koch C Cancers (Basel). 2024; 16(7).

PMID: 38611062 PMC: 11010960. DOI: 10.3390/cancers16071384.

References

Wallis C, Saskin R, Choo R, Herschorn S, Kodama R, Satkunasivam R . Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2015; 70(1):21-30. DOI: 10.1016/j.eururo.2015.11.010. View

Incrocci L, Wortel R, Alemayehu W, Aluwini S, Schimmel E, Krol S . Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016; 17(8):1061-1069. DOI: 10.1016/S1470-2045(16)30070-5. View

Dalsania R, Shah K, Stotsky-Himelfarb E, Hoffe S, Willingham F . Management of Long-Term Toxicity From Pelvic Radiation Therapy. Am Soc Clin Oncol Educ Book. 2021; 41:1-11. DOI: 10.1200/EDBK_323525. View

Carpenter T, Forsythe K, Kao J, Stone N, Stock R . Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy. 2010; 10(4):261-8. DOI: 10.1016/j.brachy.2010.10.002. View

Gomez-Aparicio M, Valero J, Caballero B, Garcia R, Hernando-Requejo O, Montero A . Extreme Hypofractionation with SBRT in Localized Prostate Cancer. Curr Oncol. 2021; 28(4):2933-2949. PMC: 8395496. DOI: 10.3390/curroncol28040257. View

Golfam M, Samant R, Eapen L, Malone S . Effects of radiation and total androgen blockade on serum hemoglobin, testosterone, and erythropoietin in patients with localized prostate cancer. Curr Oncol. 2012; 19(4):e258-63. PMC: 3410837. DOI: 10.3747/co.19.963. View

Whalley D, Hruby G, Alfieri F, Kneebone A, Eade T . SpaceOAR Hydrogel in Dose-escalated Prostate Cancer Radiotherapy: Rectal Dosimetry and Late Toxicity. Clin Oncol (R Coll Radiol). 2016; 28(10):e148-54. DOI: 10.1016/j.clon.2016.05.005. View

Zelefsky M, Kuban D, Levy L, Potters L, Beyer D, Blasko J . Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2006; 67(2):327-33. DOI: 10.1016/j.ijrobp.2006.08.056. View

Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn P, Jager H . Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016; 17(4):464-474. DOI: 10.1016/S1470-2045(15)00567-7. View

10.

Ezzell G, Galvin J, Low D, Palta J, Rosen I, Sharpe M . Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys. 2003; 30(8):2089-115. DOI: 10.1118/1.1591194. View

11.

Lawton C, Hunt D, Lee W, Gomella L, Grignon D, Gillin M . Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys. 2011; 81(1):1-7. PMC: 3132830. DOI: 10.1016/j.ijrobp.2010.05.056. View

12.

Greenberger B, Chen V, Den R . Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. Front Oncol. 2019; 9:1273. PMC: 6896415. DOI: 10.3389/fonc.2019.01273. View

13.

Wallis C, Mahar A, Choo R, Herschorn S, Kodama R, Shah P . Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016; 352:i851. PMC: 4775870. DOI: 10.1136/bmj.i851. View

14.

Faithfull S, Lemanska A, Aslet P, Bhatt N, Coe J, Drudge-Coates L . Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies. Int J Clin Pract. 2015; 69(10):1184-208. PMC: 5042099. DOI: 10.1111/ijcp.12693. View

15.

Nomiya T, Tsuji H, Kawamura H, Ohno T, Toyama S, Shioyama Y . A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). Radiother Oncol. 2016; 121(2):288-293. DOI: 10.1016/j.radonc.2016.10.009. View

16.

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M . Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196):385-395. DOI: 10.1016/S0140-6736(19)31131-6. View

17.

Michalski J, Moughan J, Purdy J, Bosch W, Bruner D, Bahary J . Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018; 4(6):e180039. PMC: 5885160. DOI: 10.1001/jamaoncol.2018.0039. View

18.

Li M, Li X, Yao L, Han X, Yan W, Liu Y . Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:709530. PMC: 8547329. DOI: 10.3389/fonc.2021.709530. View

19.

Arruda Viani G, Viana B, Martin J, Rossi B, Zuliani G, Stefano E . Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Cancer. 2016; 122(13):2004-11. DOI: 10.1002/cncr.29983. View

20.

Chorbinska J, Krajewski W, Zdrojowy R . Urological complications after radiation therapy-nothing ventured, nothing gained: a Narrative Review. Transl Cancer Res. 2022; 10(2):1096-1118. PMC: 8798528. DOI: 10.21037/tcr-20-2589. View